Close this search box.

Causal biology is the North Star of R&D, from Karuna to ADC engineering, says BMS’s Plenge

WEBCAST | Discovery & Translation

Bristol Myers’ head of research leans into CNS, modality innovation, first vs. best in class, and more on The BioCentury Show

By C. Simone Fishburn, Editor in Chief

April 18, 2024 12:05 PM UTC

Within the framework of target, modality and path to clinic, causal biology is the axis along which Robert Plenge is building and prosecuting research at BMS. It maps from late stage decisions the company has made, such as the Karuna acquisition, to strategies in early R&D, such as how to innovate in ADCs and extend the modality to new applications. 

Plenge became EVP, chief research officer and head of research at  Bristol Myers Squibb Co. (NYSE:BMY) in July 2023, having joined the company via the Celgene acquisition, where he had been head of the Inflammation & Immunology Thematic Center of Excellence…